p66Shc is an apoptotic rheostat whose targeted ROS inhibition improves MI outcomes

Haslem L., Hays J.M., Schmitz H., Matsuzaki S., Sjoelund V., Byrum S.D., Humphries K.M., Frazer J.K., Demeler B., Benbrook D.M., Tierney R.M., Duggan K.D., Hays F.A.
Publication typePosted Content
Publication date2022-04-14
Abstract
SUMMARY

p66Shc is an oxidoreductase that responds to cell stress by translocating to mitochondria, where p66Shc produces pro-apoptotic reactive oxygen species (ROS). This study identifies ROS-active p66Shc as a monomer that produces superoxide anion independent of metal ions, inhibits cytochrome c peroxidase, and is regulated by environmental condition-induced structural changes. p66Shc anti-apoptotic functions, including: cytochrome c reduction, increased electron transport chain activity, and caspase cascade inhibition were also discovered. This study also demonstrates that p66Shc is a stress-dependent rheostat of apoptosis, regulated by p66Shc-mortalin complexes. These complexes decrease pro-apoptotic ROS production, without blocking p66Shc-mediated cytochrome c reduction. However, stress disrupts p66Shc-mortalin interactions, promoting apoptosis. Tipping p66Shc’s apoptotic balance toward anti-apoptotic functions by genetic knockdown or p66Shc-selective ROS inhibition decreased pro-apoptotic effects and improved outcomes in zebrafish myocardial infarction models, representing a potential new myocardial infarction treatment with promising results.

Found 
Found 

Top-30

Journals

1
Cells
1 publication, 25%
Journal of Cardiovascular Development and Disease
1 publication, 25%
International Journal of Molecular Sciences
1 publication, 25%
Frontiers in Physiology
1 publication, 25%
1

Publishers

1
2
3
MDPI
3 publications, 75%
Frontiers Media S.A.
1 publication, 25%
1
2
3
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
4
Share